
medic devic heart valv therapi includ
tissu valv mechan valv repair product
biomed devic servic
boon ew posit long term
reiter buy rais target ew
bottom line view today announc settlement edward boston
scientif nyse buy highli posit ew net posit
long term two compani jointli announc global litig
settlement wherebi ew made one-tim payment addit
futur royalti owe either parti particular note us decis remov
litig overhang compani allow firm investor put focu
squar back tavr market growth dynam remain bullish
go see tavr model end report
overal think bsx strategi legal front fixat protect
robust ip portfolio also assur firm could sell tavr tmvr devic
around world go forward long term regard ew news reinforc stock
one top med-tech pick given potenti tavr guidanc upsid via low-
risk new product firm under-appreci earn leverag mitral/
tricuspid opportun could hit earlier impact expect
name pascal low-risk trial data readout march set fda lr
approv think come earlier expect june/juli continu
believ lr off-set headwind competit price pressur
europ potenti drive tavr growth firm initi guidanc rang
heel today announc reiter buy rate ew increas
price target
global litig settlement edward morn jointli
announc global litig settlement wherebi ew made one-tim payment
addit futur royalti owe either parti agreement
repres culmin litig across multipl geographi uk germani us
bring close could stretch much lengthier legal battl
agreement term term agreement ew made one-tim payment
addit royalti owe either parti
bsx strategi overal think bsx strategi litig front
tavr side weve seen previous play space
nyse |buy see note defend ip rather
enjoin competitor platform drive product remov market tavr
previous receiv two posit rule germani grant firm option
enjoin ew first march allow enjoin latter past
octob allow enjoin ultra region howev firm move
exercis injunct either case
increas price target ew deriv price target
appli price-to-earnings pro forma ep
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
buy unchang target price januari
biomed devic servic
p/e/g valuat financi metric use current mean large-cap medic devic price-to-earnings multipl ex outlier med-tech comp group ep compound-annual-growth-rate forward impli forma ep growth forward p/e/g multipl price-to-earnings multipl forma mo figur tavi
buy unchang target price januari
biomed devic servic
symptomat patient year year year american age aortic age sever sever symptomat etiolog s/ ssa primari etiolog pe patient yr severe/symptomat ssa pe patient yr yr severe/symptomat ssa pe patient consid high risk surgeri consid intermedi risk surgeri consid risk surgeri consid high risk surgeri consid intermedi risk surgeri consid risk surgeri tavr market opportun tavr market opportun aortic stenosi elderli diseas preval number candid transcathet aortic valv replac meta-analysi model studi canaccord genuiti estim -conserv assum preval old age euroheart survey primari reason age lv canccord genuiti primari research ew compani report investor day assum ou market europe/japan us figur tavi ww market share
buy unchang target price januari
biomed devic servic
edward lifesci averag implant center total unit total ew ww tavi revenu ex growth averag total unit total ww tavi revenu growth averag total unit total ww tavi revenu growth player ww tavi revenu ww implant patient popul player tavi ww revenu market lifesci implant averag implant total unit asp ew us revenu averag total unit asp total us revenu averag total unit asp us revenu player us revenu us implant address patient penetr us tavr market figur tavi eu/row market share
buy unchang target price januari
biomed devic servic
detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact inform appear front page report
buy unchang target price januari
biomed devic servic
million except per share revenu gross oper expens incom pre-tax incom tax interest exp eitf add-back net incom share ep forma ex ia margin analysi gross margin pro sale sale y/i revenu growth growth growth incom pro forma incom forma ex-one-tim ia figur revenu model
buy unchang target price januari
biomed devic servic
heart valv aortic/mitr replacement/repairaort tavi sapien product royalti us total tavi mitral/trucuspid total tmvr/re total transcathet valv therapi surgic heart valv therapytissu repair surgic heart valv cardiac surgeri cardiac surgeri total surgic hv cs surgic valv consign total surgic hv/c revenu critic hemodynam pressur critic vascular vascular total critic vascular revenu pro forma total revenu figur revenu model part
buy unchang target price januari
biomed devic servic
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin januari et
date time product januari et
deriv price target appli price-to-earnings pro forma ep
price target support rel valuat analysi
price target predic ev/sal multipl discount small cap median out-year multipl
appli nvro revenu
risk achiev target price valuat
heart valv competit environ transcathet valv expect may high gener risk inher compani
particip medic devic space also appli edward includ risk advers chang reimburs long regulatori
pathway approv new class medic devic robust competit environ well devic recal may
impact compani financi could also expos compani litig
tmvr market lucr drive high level competit mitral valv diseas repres larg highli under-penetr market
provid signific opportun minimally-invas mr therapi product ew platform one first tmvr devic
enter clinic phase number compani also develop product could potenti compet ew
current involv outstand patent litig relat tavr relat
firm also expos product liabil litig stem transvagin surgic mesh tvm product juli
final stage enter master settlement agreement approxim known claim
relat tvm
establish product liabil accrual known project futur claim firm continu gener
solid greater-than-anticip claim liabil well higher-than-anticip legal expens relat outstand patent
futur project growth rate estim larg depend pipelin portfolio execut incur signific setback
delay bring new product market futur growth could neg impact
deriv signific percentag sale de portfolio busi compet matur
market histor face price pressur market shown sign stabil past month
acceler asp degrad and/or deterior market fundament could neg impact bsx growth profil
execut multipl acquisit past year consist manag focu expand near
adjac howev investor know materi risk associ integr acquir asset boston scientif
unsuccess manag integr new compani could neg impact firm abil achiev intern
buy unchang target price januari
biomed devic servic
intellectu properti nvro abil defend ip retain monopoli high frequenc paresthesia-fre therapi
import compani current legal disput like continu least competitor abl
invalid nvro core ip
provid hf protect compani could face competit hf realm could impact growth profil
vertic integr current outsourc manufactur reli complet third-parti compani
manufactur assembl senza system sole/single-sourc supplier manag state
plan bring manufactur hous thu potenti suppli issu remain outstand risk
coverag reimburs util close like reimburs level favor reimburs current
avail physicians/pati remain fairli stabl past sever year and/or privat payor
significantli chang current reimburs polici senza adopt could materi impact also note privat payor
push back senza reimburs label devic investig abl overturn
decis current futur lack privat payor coverag could pose issu
market compris mani larg well-capit compani compet mani larg well-capit med-tech
compani long histori neuromodul space well-entrench physician relationship compani
also much broader neuromodul portfolio allow firm leverag breadth includ bundl captur
addit share unabl leverag strong rct data drive physician adopt disrupt competitor physician-rep
relationship compani growth prospect could neg impact
 market health larg dictat nvro long-term potenti market current repres world-wide
market nvro futur growth larg tie health domest market firm abil continu captur
share legaci player space
revenu concentr around singl platform revenu sole deriv senza platform addit product
current compani pipelin compani face suppli manufactur regulatori issu nvro abil suppli
custom gener revenu could significantli impair
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
